Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6150378 | 0.83 | BACE1 (0.51) | BACE1KDM4EPKMFPR2FAAH | |
| SCHEMBL3937273 | 0.80 | MEN1 (0.34) | MAPTTHRBSMN1; SMN2 | |
| SCHEMBL30476293 | 0.80 | UTS2R (0.49) | BACE1KDM4EPKMFPR2UTS2R | |
| SCHEMBL20057040 | 0.79 | BACE1 (0.53) | BACE1KDM4EPKMFPR2FAAH | |
| SCHEMBL6149643 | 0.79 | FPR2 (0.48) | BACE1KDM4EPKMFPR2FAAH | |
| SCHEMBL20580747 | 0.78 | UTS2R (0.48) | BACE1KDM4EPKMFPR2UTS2R | |
| SCHEMBL2318246 | 0.78 | MAPT (0.48) | BACE1KDM4ERECQLMAPTTHRB | |
| SCHEMBL18326363 | 0.78 | UTS2R (0.44) | BACE1FPR2UTS2RGPR119 | |
| SCHEMBL15864070 | 0.76 | BACE1 (0.46) | BACE1KDM4EPKMFPR2FAAH | |
| SCHEMBL5573169 | 0.75 | HPGD (0.53) | KDM4EPKMFAAHRECQLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | disclosed |
| US-7781590-B2 | Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20070021403-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | BACE1 503/4885KDM4E 2110/4885PKM 2560/4885 |
| US-20070021403-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | BACE1 453/4885KDM4E 1997/4885PKM 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.